Ignite Creation Date:
2024-05-05 @ 10:00 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00001685
Status:
COMPLETED
Last Update Posted:
2008-03-04
First Post:
1999-11-03
Brief Title:
Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens MART-1 GP100 and Tyrosinase
Sponsor:
National Cancer Institute NCI
Organization:
National Institutes of Health Clinical Center CC
Study Overview
Official Title:
Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens MART-1 GP100 and Tyrosinase
Status:
COMPLETED
Status Verified Date:
1999-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a study of a melanoma tumor antigen peptide vaccine Peptides representing HLA-A201 restricted T cell epitopes of the melanoma antigens MART-1 gp100 and tyrosinase will be administered emulsified in Incomplete Freunds Adjuvant IFA to HLA-A201 patients with melanoma The study is designed to evaluate the potential therapeutic role immunologic effects and toxicity of repeated doses of this peptide vaccine administered subcutaneously
Immune reactivity to the peptide epitope will be monitored in all patients by analysis of melanoma-specific T cell precursors prior to and after immunization
Immune reactivity to the peptide epitope will be monitored in all patients by analysis of melanoma-specific T cell precursors prior to and after immunization
Detailed Description:
This is a study of a melanoma tumor antigen peptide vaccine Peptides representing HLA-A201 restricted T cell epitopes of the melanoma antigens MART-1 gp100 and tyrosinase will be administered emulsified in Incomplete Freunds Adjuvant IFA to HLA-A201 patients with melanoma The study is designed to evaluate the potential therapeutic role immunologic effects and toxicity of repeated doses of this peptide vaccine administered subcutaneously
Immune reactivity to the peptide epitope will be monitored in all patients by analysis of melanoma-specific T cell precursors prior to and after immunization
Immune reactivity to the peptide epitope will be monitored in all patients by analysis of melanoma-specific T cell precursors prior to and after immunization
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 98-C-0023 | None | None | None |